Mark Cuban read­ies to fight Hu­mi­ra's megablock­buster fran­chise next month

Mark Cuban’s Cost Plus Drugs Com­pa­ny said to­day that it’s to com­pete with Ab­b­Vie’s mul­ti-bil­lion-dol­lar Hu­mi­ra fran­chise by en­ter­ing the biosim­i­lar fray along­side more than a half dozen oth­er com­peti­tors this year.

Cuban is work­ing with Co­herus Bio­Sciences, which won ap­proval for its Hu­mi­ra biosim­i­lar Yusim­ry (adal­i­mum­ab-aqvh) in De­cem­ber 2021 and ex­pects to launch at an 85% dis­count to Hu­mi­ra.

“There are tens of mil­lions of peo­ple who are unin­sured or un­der in­sured, many we hear from all the time, that now have a more af­ford­able op­tion,” Cuban told End­points News via email. “And now in­sur­ers and PBMs that work with us al­so have a more af­ford­able op­tion for their mem­bers. There is on­ly up­side to Yusim­ry from Co­herus.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER